Brazil has gathered enough infection data from a late-stage trial of an experimental COVID-19 vaccine developed by China’s Sinovac Biotech and expects to have interim results on its efficiency in early December, trial organizers said on Monday, reported Reuters.
The director of Butantan research institute in Sao Paulo, Dimas Covas, stated that the institute has 74 confirmed cases among its trial participants, above the initial 61 milestone set for interim efficiency analysis.
He also said an independent committee is likely to release the efficiency results in the first week of December based on its analysis of the data. According to Reuters, Dimas Covas said Brazil’s health ministry now has all the information needed to include Coronavac in the national program, while São Paulo Health Secretary Jean Gorinchteyn expected on Monday Brazil’s regulator to approve the use of the Sinovac vaccine, CoronaVac, by January.
João Gabbardo, head of the Sao Paulo’s COVID-19 contingency committee, said at the same event that he expects China’s health regulator to approve Sinovac’s CoronaVac in December, which could hasten approval in Brazil.
According to Valor Econômico, Russia announced on Tuesday that its “Sputnik V” vaccine was 91.4% effective in preventing COVID-19, 28 days after the first dose was applied, in the second battery of preliminary clinical trial data. The effectiveness of “Sputnik V” would be 95% at the end of 42 days after the first dose and seven days after the second dose.
Preliminary data from clinical tests indicate the effectiveness of the immunizer at the same level as vaccines from Pfizer and Moderna laboratories and better than in the case of the AstraZeneca vaccine.
As Valor reported, the vaccine will cost less than $10 a dose for international markets and will start to be produced soon in Brazil, according to the fund that manages the development of the vaccine.
According to the Russians, storing the Sputnik V will also be easy. “The Sovereign Fund and its partners launched the production of the lyophilized (dry) form of the vaccine, which is stored at a temperature of +2 to +8 Celsius degrees.” According to the fund, it allows the distribution of the vaccine in international markets, in addition to expanding its use in regions of difficult access, including areas of a tropical climate, such as Africa and Latin America.